Literature DB >> 7642288

Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

A Aase1, G Bjune, E A Høiby, E Rosenqvist, A K Pedersen, T E Michaelsen.   

Abstract

Opsonic activity in sera from 27 military recruits vaccinated with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine was measured as respiratory burst with polymorphonuclear leukocytes as the effector cells and meningococci of the epidemic strain as the target. The results were compared with antimeningococcal IgG antibodies against an outer membrane vesicle coat in an enzyme-linked immunosorbent assay and with serum bactericidal activity. The vaccinees were immunized twice, with a 6-week interval between the two. The serum samples studied were collected at day zero, after 6 weeks, and after 12 weeks. Both serum bactericidal activity and respiratory burst were measured by adding external serum as the complement source. The results revealed a significant increase in specific IgG response, serum bactericidal activity, and respiratory burst after vaccination. We found a highly significant correlation between the responses in all three assays (P < 0.0001). The highest correlation was found between respiratory burst and antimeningococcal IgG response (r = 0.93). This result strongly indicates that respiratory burst is mediated almost exclusively by IgG antibodies. The correlation between antimeningococcal IgG response and serum bactericidal activity was slightly lower (r = 0.83). The correlation between respiratory burst and serum bactericidal activity was further reduced (r = 0.78), and some of the sera revealed a marked preference for only one of the activities. This result means that respiratory burst and serum bactericidal activity in part are induced by different mediators, and to obtain a more complete picture of the potential protective activity, both assays should be applied to survey a vaccine trial.

Mesh:

Substances:

Year:  1995        PMID: 7642288      PMCID: PMC173489          DOI: 10.1128/iai.63.9.3531-3536.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen.

Authors:  S Harthug; E Rosenqvist; E A Høiby; T W Gedde-Dahl; L O Frøholm
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

2.  Factors important for the measurement of chemiluminescence production by polymorphonuclear leukocytes.

Authors:  A Halstensen; B Haneberg; J Glette; S Sandberg; C O Solberg
Journal:  J Immunol Methods       Date:  1986-04-03       Impact factor: 2.303

3.  Human opsonins to meningococci after vaccination.

Authors:  A Halstensen; B Haneberg; L O Frøholm; V Lehmann; C E Frasch; C O Solberg
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

4.  Standardization of a chemiluminescence method for the measurement of meningococcal opsonins using ethanol fixed meningococci.

Authors:  A Halstensen; B Haneberg
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1987-08

5.  Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting.

Authors:  E Wedege; L O Frøholm
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

6.  Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals.

Authors:  S C Ross; P J Rosenthal; H M Berberich; P Densen
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

Review 7.  Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency.

Authors:  S C Ross; P Densen
Journal:  Medicine (Baltimore)       Date:  1984-09       Impact factor: 1.889

8.  Antibody-dependent mononuclear cell-mediated antimeningococcal activity. Comparison of the effects of convalescent and postimmunization immunoglobulins G, M, and A.

Authors:  G H Lowell; L F Smith; J M Griffiss; B L Brandt; R P MacDermott
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

9.  A comparison of human and murine monoclonal IgGs specific for the P1.7 PorA protein of Neisseria meningitidis.

Authors:  A Delvig; S Jahn; B Kusecek; J E Heckels; E Rosenqvist; E A Høiby; T E Michaelsen; M Achtman
Journal:  Mol Immunol       Date:  1994-11       Impact factor: 4.407

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  20 in total

1.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Construction and functional activities of chimeric mouse-human immunoglobulin G and immunoglobulin M antibodies against the Neisseria meningitidis PorA P1.7 and P1.16 epitopes.

Authors:  Terje E Michaelsen; Øistein Ihle; Karen Johanne Beckstrøm; Tove K Herstad; Jan Kolberg; E Arne Høiby; Audun Aase
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

3.  Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.

Authors:  E Wedege; K Bolstad; A Aase; T K Herstad; L McCallum; E Rosenqvist; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

4.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine.

Authors:  O Pérez; M Lastre; J Lapinet; G Bracho; M Díaz; C Zayas; C Taboada; G Sierra
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

7.  Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry.

Authors:  J S Plested; B L Ferry; P A Coull; K Makepeace; A K Lehmann; F G MacKinnon; H G Griffiths; M A Herbert; J C Richards; E R Moxon
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Authors:  C L Vermont; H H van Dijken; C J P van Limpt; R de Groot; L van Alphen; G P J M van Den Dobbelsteen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

9.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies.

Authors:  Bernt Christian Hellerud; Audun Aase; Tove Karin Herstad; Lisbeth Meyer Naess; Lisa Høyem Kristiansen; Anne-Marie Siebke Trøseid; Morten Harboe; Knut Tore Lappegård; Petter Brandtzaeg; E Arne Høiby; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.